

SUSTAINED RELEASE ORAL FORMULATION FOR TREATMENT OF PARKINSON'S DISEASE

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is also accepting healthy volunteers

Inclusion Criteria:

- Normal healthy - 18-65 years of age - Not currently taking medications regularly - Able to fast 6 hours, only water allowed

Conditions & Interventions

Interventions:

Drug: levodopa/carbidopa oral formulation A, Drug: levodopa/carbidopa oral formulation B

Conditions:

Brain & Nervous System

Keywords:

Healthy adults

More Information

Description: LD/CD (medications to treat Parkinson's disease) will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. The combination of CD/LD in the inner sachet varies from that in the outer sachet. This allows for sequential release of CD and then LD to mimic a CD pretreatment method which is known to increase LD absorption and prolong its half-life.

Study Contact: Khalaf Bushara - busha001@umn.edu

Principal Investigator: Khalaf Bushara

Phase: EARLY_PHASE1

IRB Number: STUDY00024501

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.